BK2014 Medical Instruments & Supplies
- 1127.221
- +18.402+1.66%
What's Going On With NVIDIA Stock Today?
NVIDIA Corporation (NASDAQ:NVDA) shares are trading higher on Wednesday.In a blog post, the company said that a collaboration between NVIDIA and academic researchers is prepping robots for surgery.ORB
$100 Invested In Intuitive Surgical 10 Years Ago Would Be Worth This Much Today
Intuitive Surgical (NASDAQ:ISRG) has outperformed the market over the past 10 years by 14.72% on an annualized basis producing an average annual return of 25.62%. Currently, Intuitive Surgical has a m
Nyxoah Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Sales Results.
Nyxoah Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Sales Results.
Most Shorted S&P 500 Stocks as a Percentage of Float
Short Interest in S&P 500 Healthcare Sector Dips in April, Biotechnology Companies Most Shorted
OPEN, BCRX and AWIN Among Pre-market Gainers
Sanara MedTech Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 40.04% Cantor Fitzgerald → $44 Reiterates Overweight → Overweight 03/27/2024 40.04% Cantor Fitz
Alcon Analysts Increase Their Forecasts Following Q1 Results
Alcon Inc. (NYSE:ALC) posted mixed first-quarter financial results, after the closing bell on Monday.Alcon posted adjusted earnings of 78 cents per share, beating market estimates of 73 cents per shar
Benchmark Reiterates Speculative Buy on Nephros, Maintains $5 Price Target
Benchmark analyst Robert Wasserman reiterates Nephros (NASDAQ:NEPH) with a Speculative Buy and maintains $5 price target.
Nephros Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 138.1% Benchmark → $5 Reiterates Speculative Buy → Speculative Buy 03/08/2024 138.1% Benchmark
Nyxoah Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 164.45% Stifel $27 → $27 Maintains Buy 03/25/2024 115.48% HC Wainwright & Co. → $22 Reiterates
Goldman Sachs Maintains Neutral on Singular Genomics Sys, Lowers Price Target to $0.75
Goldman Sachs analyst Matthew Sykes maintains Singular Genomics Sys (NASDAQ:OMIC) with a Neutral and lowers the price target from $0.85 to $0.75.
Singular Genomics Sys Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 85.19% Goldman Sachs $0.85 → $0.75 Maintains Neutral 03/20/2024 23.46% UBS $0.4 → $0.5 Maintain
Predictive Oncology Q1 EPS $(1.04) Compared to $(0.86) YoY, Sales $419.6K Up From $239.9K YoY
Predictive Oncology Q1 EPS $(1.04) Compared to $(0.86) YoY, Sales $419.6K Up From $239.9K YoY
Needham Maintains Buy on Alcon, Raises Price Target to $101
Needham analyst David Saxon maintains Alcon (NYSE:ALC) with a Buy and raises the price target from $98 to $101.
Nyxoah Q1 2024 GAAP EPS $(0.45) Misses $(0.42) Estimate, Sales $1.33M Beat $1.31M Estimate
Nyxoah (NASDAQ:NYXH) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.42) by 7.14 percent. This is a 8.16 percent increase over losses of $(0.49) per s
How Is The Market Feeling About West Pharmaceutical Servs?
West Pharmaceutical Servs's (NYSE:WST) short percent of float has fallen 13.37% since its last report. The company recently reported that it has 975 thousand shares sold short, which is 1.75% of all r
JAN, MTC and PROK Among Mid-day Movers
Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Alibaba Group Holding Limited (NYSE:BABA) fell sharply during Tuesday's session following mixed first-quarter financial results.The e-commerce giant reported fiscal fourth-quarter 2023 reven
Akoya BioSciences Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results and Cut Its FY24 Revenue Guidance Below Estimates. Also, BTIG Maintained a Buy Rating on the Stock but Lowered Its Price Target From $9 to $6.
Akoya BioSciences Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results and Cut Its FY24 Revenue Guidance Below Estimates. Also, BTIG Maintained a Buy Rating on